Combined suicide and cytokine gene therapy for peritoneal carcinomatosis

Gut

Volumn 47, Issue 3, 2000, Pages 343-348

  Lechanteur, C ^a   Princen, F ^a   Delvenne, P ^a   Lopez, M ^a   Fillet, G ^a   Gielen, J ^a   Merville, M P ^a   Bours, V ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Gene therapy; Granulocyte macrophage colony stimulating factor; Interleukin 12; Peritoneal carcinomatosis; Thymidine kinase

Indexed keywords

CYTOKINE; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; THYMIDINE KINASE;

ADOLESCENT; ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNOTHERAPY; CANCER MODEL; CARCINOMATOUS PERITONITIS; CONTROLLED STUDY; GENE THERAPY; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LYMPHOCYTIC INFILTRATION; MACROPHAGE; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL; T LYMPHOCYTE SUBPOPULATION;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD8; ANTIVIRAL AGENTS; CARCINOMA; CYTOKINES; DISEASE-FREE SURVIVAL; GANCICLOVIR; GENE THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INTERLEUKIN-12; MACROPHAGES; PERITONEAL NEOPLASMS; RATS; RECEPTORS, INTERLEUKIN-2; SIMPLEXVIRUS; T-LYMPHOCYTES; THYMIDINE KINASE; TREATMENT OUTCOME;

EID: 0033857586     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.47.3.343     Document Type: Article

References (40)

1. 1 Freeman SM, Whartenby KA, Freeman JL, et al. In situ use of suicide genes for cancer therapy. Semin Oncol 1996;23:31-45.
2. 2 Moolten FL, Wells JM, Heyman RA, et al. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther 1990;1:125-34.
3. 3 Lechanteur C, Princen F, Lo Bue S, et al. HSV-1 thymidine kinase gene therapy for colorectal adenocarcinoma-derived peritoneal carcinomatosis. Gene Ther 1997;4:1189-94.
4. 4 Princen F, Lechanteur C, Lopez M, et al. Repeated cycles of retrovirus-mediated HSVtk gene transfer plus ganciclovir increase survival of rats with peritoneal carcinomatosis. Gene Ther 1998;5:1054-60.
5. 5 Barba D, Hardin J, Ray J, et al. Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg 1993;79:729-35.
6. 6 Caruso M, Panis Y, Gagandeep S, et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Prac Nad Acad Sci USA 1993:90:7024-8.
7. 7 Culver KW, Ram Z, Walbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-2.
8. 8 Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990;82:297-300.
9. 9 Maron A, Gustin T, Le Roux A, et al. Gene therapy of rat C6 glioma using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene: long-term follow-up by magnetic resonance imaging. Gene Ther 1996; 3:315-22.
10. 10 Ram Z, Culver KW, Walbridge S, et al. In situ retroviral-mediated gene transfer for treatment of brain tumors in rats. Cancer Res 1993;53:83-8.
11. 11 Sterman DH, Treat J, Litzky A, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;7:1083-92.
12. 12 Chen C-Y, Chang Y-N, Ryan P, et al. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect". Hum Gene Ther 1995;6:1467-76.
13. 13 Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander-effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53: 5274-83.
14. 14 Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet 1997;349:2-3.
15. 15 Cavallo F, Signorelli P, Giovarelli M, et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997;89:1049-58.
16. 16 Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12. J Immunol 1995;155:1393-403.
17. 17 Bramson JL, Hitt M, Addison CL, et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gen Ther 1996;7:1995-2002.
18. 18 Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
19. 19 Lode HN, Dreier T, Xiang R, et al. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA 1998;95:2475-80.
20. 20 Rakhmilevich AL, Turner J, Ford MJ, et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine Tumors. Proc Natl Acad Sci USA 1996; 93:6291-6.
21. 21 Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154: 6466-74.
22. 22 Qin H, Chatterjee K. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum Gene Ther 1996;7:1853-60.
23. 23 Yu JS, Burwick JA, Dranoff G, et al. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 1997;8:1065-72.
24. 24 Lee C-T, Wu S, Ciernik F, et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1997;8:187-93.
25. 25 Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
26. 26 Cosset F-L, Takeuchi Y, Batttini J-L, et al. High-liter packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995;69:7430-6.
27. 27 Perrin P, Cassagnau E, Burg C, et al. An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology 1994;107:1697-708.
28. 28 Barba D, Hardin J, Sadelain M, et al. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994;91:4348-52.
29. 29 Vile RG, Nelson JA, Castleden S, et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune system. Cancer Res 1994;54:6228-34.
30. 30 Vile RG, Castleden S, Marshall J, et al. Generation of an anti-tumor immune response in a non-immunogenic tumor: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a TH1-like profile of intratumoral cytokine expression. Int J Cancer 1997;71:267-74.
31. 31 Felzmann T, Ramsey W, Blaese R. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Ther 1997;4:1322-9.
32. 32 Gagandeep S, Brew R, Green B, et al. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". Cancer Gene Ther 1996;3: 83-8.
33. 33 Ramesh R, Marrogi AJ, Munshi A, et al. In vivo analysis of the "bystander effect": a cytokine cascade. Exp Hematol 1996;24:829-38.
34. 34 Bonnekoh B, Greenhalgh DA, Chen S-H, et al. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model. J Invest Dermatol 1998;110:867-71.
35. 35 Hayashi S, Emi N, Yokoyama I, et al. Inhibition of establishment of hepatic metastasis in mice by combination gene therapy using both herpes simplex virus-thymidine kinase and granulocyte macrophage-colony stimulating factor genes in murine colon cancer. Cancer Gene Ther 1997;4:339-44.
36. 36 Coll J-L, Mesnil M, Lefebvre M-F, et al. Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ ganciclovir and IL-2 treatments. Gene Ther 1997;4:1160-6.
37. 37 Chen S, Li Chen XH, Wang Y, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995;92:2577-81.
38. 38 Chen S-H, Kosai K-I, Xu B, et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996;56:3758-62.
39. 39 Consalvo M, Mullen CA, Modesti A. 5-Fluorocytosine induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995; 154:5302-12.
40. 40 Misawa T, Chiang MH, Pandit L, Gordon EM, Anderson WF, Parekh D, Development of systemic immunologic responses against hepatic metastases during gene therapy for peritoneal carcinomatosis with retroviral Hs-tk and ganciclovir. J Gastrointest Surg 1997;1:527-33.